New chemical entities (NCEs) are patent-protected pharmaceutical compounds that may be produced only by the patent holder or any company authorized for their production or usage. Bachem manufactures NCEs for diagnostic or therapeutic purposes in most cases exclusively on behalf of biotech or pharmaceutical companies.

NCEs undergo a rigorous routine of preclinical and clinical studies, from discovery up to potential market launch. In early development phases, these compounds are requested only in small quantities.

As the world leading peptide manufacturer, Bachem is currently involved in more than 100 cGMP projects targeting New Chemical Entities.

A growing number of experienced Key Account Managers attend to your special needs and requirements. We are confident in all of our professional abilities and capabilities to help you achieve success in your project.

Bachem has almost 40 years of experience in the development, production and filing of peptide active pharmaceutical ingredients (APIs). To learn more about our capabilities in development, production, regulatory affairs and how to manage such a project please contact us.

What's it like to work with us? See testimonials.